|
14.01.2025 13:37:21
|
ORIC Pharma Stock Climbs On Clinical Supply Deal With J&J's Janssen For ORIC-114
(RTTNews) - Shares of ORIC Pharmaceuticals, Inc. (ORIC) gained around 8 percent on Monday's regular trading on the Nasdaq and is currently 10 percent higher in the pre-market activity, after the clinical stage oncology company announced that it has entered into a supply agreement with Janssen Research & Development LLC, affiliated to drug major Johnson & Johnson (JNJ), to evaluate ORIC-114.
Under the deal, the companies will study ORIC-114, a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor, in combination with subcutaneous amivantamab, Johnson & Johnson's fully-human EGFR-MET bispecific antibody, for the first-line treatment of patients with advanced non-small cell lung cancer or NSCLC with EGFR exon 20 insertion mutations.
ORIC said it expects to initiate the combination Phase 1b trial to evaluate the safety and tolerability of ORIC-114 in combination with SC amivantamab for the first-line treatment of patients with advanced NSCLC with EGFR exon 20 insertion mutations in the first quarter of 2025.
The primary objectives of the Phase 1b trial are to determine the provisional recommended Phase 2 dose or RP2D for the combination, and additional objectives include assessment of efficacy and further characterization of the safety profile of ORIC-114 in combination with SC amivantamab.
ORIC will conduct and sponsor the trial and Johnson & Johnson will provide SC amivantamab.
The company expects to report initial data from the trial in mid-2026.
ORIC maintains development and commercial rights to ORIC-114 and is free to expand the program in combination with other agents.
The company noted that ORIC-114 has already demonstrated encouraging systemic and intracranial activity in heavily pre-treated patients with EGFR/HER2 mutated NSCLC.
Jacob Chacko, ORICchief executive officer, said, "Given the prevalence of brain metastases across all lines of EGFR exon 20 NSCLC, we aim to further explore ORIC-114s emerging profile in the first-line setting both as a monotherapy and in combination with SC amivantamab."
On the Nasdaq, ORIC Pharma shares closed Monday's regular trading at $8.60, up 8.04 percent. In pre-market activity, the shares were gaining around 10.4 percent to trade at $9.49.
For More Such Health News, visit rttnews.com https://www.rttnews.com/content/health.aspx
Nachrichten zu Johnson & Johnson
|
29.01.25 |
Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: Wäre eine Anlage in Johnson Johnson von vor 5 Jahren lukrativ gewesen? (finanzen.ch) | |
|
28.01.25 |
Freundlicher Handel: Dow Jones beendet den Dienstagshandel in der Gewinnzone (finanzen.ch) | |
|
27.01.25 |
Börse New York: Dow Jones präsentiert sich zum Handelsende fester (finanzen.ch) | |
|
27.01.25 |
Handel in New York: Dow Jones am Montagnachmittag mit positivem Vorzeichen (finanzen.ch) | |
|
27.01.25 |
Börse New York in Rot: Dow Jones zeigt sich leichter (finanzen.ch) | |
|
27.01.25 |
Handel in New York: Dow Jones zum Start im Minus (finanzen.ch) | |
|
23.01.25 |
Pluszeichen in New York: Dow Jones notiert am Mittag im Plus (finanzen.ch) | |
|
23.01.25 |
Dow Jones-Handel aktuell: Dow Jones beginnt Sitzung weit in der Gewinnzone (finanzen.ch) |
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
NEU✅ Meta Platforms
NEU✅ Microsoft
inklusive Rebalancing:
❌ Arthur J. Gallagher & Co
❌ Progressive
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Johnson & Johnson | 135.40 | -2.71% |
|
| ORIC Pharmaceuticals Inc Registered Shs | 12.39 | 15.47% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Wall Street schlussendlich etwas höher -- SMI schliesst im Plus -- DAX zum Handelsende fester -- Börsen in Fernost letztlich uneinig - Nikkei stabilDer heimische und der deutsche Aktienmarkt präsentierten sich zur Wochenmitte freundlich. Die US-Börsen gewannen zur Wochenmitte leicht hinzu. Auch die asiatischen Indizes gaben indes überwiegend nach, lediglich der Nikkei hielt sich knapp im Plus.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |